PubRank

Gilbert Deray

Author PubWeight™ 113.25‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 2005 1.87
2 Antiretroviral and immunosuppressive drug-drug interactions: an update. Kidney Int 2004 1.74
3 Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 2007 1.73
4 Vaccination and chronic kidney disease. Nephrol Dial Transplant 2007 1.63
5 Thrombotic microangiopathy and anti-VEGF agents. Nephrol Dial Transplant 2006 1.61
6 Ear and kidney syndromes: molecular versus clinical approach. Kidney Int 2004 1.59
7 Changing electrolyte and acido-basic profile in HIV-infected patients in the HAART era. Nephron Physiol 2006 1.51
8 Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 2004 1.50
9 Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis 2007 1.49
10 Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 2005 1.49
11 Bone mineral density and fracture prevalence in long-term kidney graft recipients. Transplantation 2002 1.47
12 L-carnitine treatment in incident hemodialysis patients: the multicenter, randomized, double-blinded, placebo-controlled CARNIDIAL trial. Clin J Am Soc Nephrol 2012 1.44
13 Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int 2004 1.43
14 Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol 2008 1.43
15 Lamivudine and HBV-associated nephropathy. Nephrol Dial Transplant 2005 1.40
16 Once-weekly erythropoietic therapy: is there a difference between the available preparations? Nephrol Dial Transplant 2003 1.40
17 Drug-induced Fanconi's syndrome. Am J Kidney Dis 2003 1.38
18 Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anticancer Drugs 2009 1.26
19 Kidney disease in patients with HIV infection and AIDS. Clin Infect Dis 2008 1.25
20 Is serum cystatin-C a reliable marker for metabolic syndrome? Am J Med 2008 1.24
21 Renal tubular drug transporters. Nephron Physiol 2006 1.20
22 Primary chronic interstitial nephritis in Crohn's disease. Gastroenterology 2002 1.19
23 Herbs and the kidney. Am J Kidney Dis 2004 1.16
24 Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant 2006 1.08
25 Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword? J Am Soc Nephrol 2013 1.07
26 Angiotensin-converting enzyme inhibitor-induced syndrome of inappropriate secretion of antidiuretic hormone: case report and review of the literature. Clin Pharmacol Ther 2002 1.06
27 Abnormal blood pressure circadian rhythm: a target organ damage? Int J Cardiol 2006 1.06
28 Acute Tubular Necrosis and Interstitial Nephritis during Pemetrexed Therapy. Case Rep Oncol 2009 1.04
29 Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study. Eur J Radiol 2009 1.03
30 Adefovir dipivoxil-induced acute tubular necrosis and Fanconi syndrome in a renal transplant patient. AIDS 2009 1.01
31 Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study. J Am Soc Nephrol 2002 1.01
32 Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients. Med Sci Monit 2004 1.00
33 A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet Genomics 2005 0.99
34 Renal tubular transporters and antiviral drugs: an update. AIDS 2005 0.99
35 Renal safety of gadolinium-based contrast media in patients with chronic renal insufficiency. Radiology 2009 0.98
36 Lung cancer and renal insufficiency: prevalence and anticancer drug issues. Lung 2008 0.98
37 Hemoglobin variability in nondialysis chronic kidney disease: examining the association with mortality. Clin J Am Soc Nephrol 2009 0.97
38 Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. Breast Cancer Res Treat 2008 0.97
39 Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome? J Natl Cancer Inst 2007 0.96
40 Diagnosis and management of anaemia and iron deficiency in patients with haematological malignancies or solid tumours in France in 2009-2010: the AnemOnHe study. Eur J Cancer 2011 0.96
41 Kidney diseases in HIV/HCV-co-infected patients. AIDS 2009 0.95
42 Sunitinib malate. Cancer Chemother Pharmacol 2006 0.92
43 Outcome and prognosis factors in HIV-infected hemodialysis patients. Clin J Am Soc Nephrol 2006 0.92
44 Acute renal failure associated with the new BRAF inhibitor vemurafenib: a case series of 8 patients. Cancer 2014 0.91
45 Retroperitoneal fibrosis due to Wegener's granulomatosis: a misdiagnosis as tuberculosis. Am J Med 2002 0.90
46 Prevalence of renal abnormalities in chronic HBV infection: the HARPE study. Liver Int 2014 0.90
47 Effect of catheter-lock solutions on catheter-related infection and inflammatory syndrome in hemodialysis patients: heparin versus citrate 46% versus heparin/gentamicin. Blood Purif 2010 0.90
48 Drug management of prostate cancer: prevalence and consequences of renal insufficiency. Clin Genitourin Cancer 2009 0.88
49 Eye and kidney: from clinical findings to genetic explanations. J Am Soc Nephrol 2003 0.88
50 Fanconi syndrome associated with didanosine therapy. AIDS 2005 0.88
51 Pharmacokinetics and dosage adjustment of oseltamivir and zanamivir in patients with renal failure. Nephrol Dial Transplant 2006 0.88
52 Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma. Urol Oncol 2009 0.88
53 Central venous stenosis as a complication of ipsilateral haemodialysis fistula and pacemaker. Nephrol Dial Transplant 2005 0.87
54 Tubular transporters and clearance of adefovir. Eur J Pharmacol 2006 0.86
55 Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study. Crit Rev Oncol Hematol 2008 0.86
56 Immune reconstitution inflammatory syndrome and acute granulomatous interstitial nephritis. AIDS 2007 0.85
57 Clinical review: use of vancomycin in haemodialysis patients. Crit Care 2002 0.85
58 Antiretroviral drug dosing errors in HIV-infected patients undergoing hemodialysis. Clin Infect Dis 2007 0.85
59 Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients. Int J Cardiol 2005 0.84
60 Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study. Liver Transpl 2009 0.84
61 Dosing guidelines for fluconazole in patients with renal failure. Nephrol Dial Transplant 2003 0.84
62 Antiretroviral nephrotoxicities. Semin Nephrol 2008 0.84
63 Pharmacokinetics of tenofovir in haemodialysis. Nephrol Dial Transplant 2003 0.83
64 Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: the Prospective Fibrose Nephrogénique Systémique study. Invest Radiol 2014 0.83
65 Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure. Clin Pharmacokinet 2005 0.83
66 [Position statements regarding usage of biosimilars of Epoetins. Position paper of the Société de néphrologie, Société francophone de dialyse, and Société de néphrologie pédiatrique]. Nephrol Ther 2008 0.83
67 Drug-induced diabetes mellitus. Expert Opin Drug Saf 2005 0.83
68 Renal outcome after ciclosporin-induced nephrotoxicity. Nephrol Dial Transplant 2006 0.82
69 Malaria prophylaxis in patients with renal impairment: a review. Drug Saf 2013 0.82
70 [Renal toxicity of contrast agents in oncologic patients]. Bull Cancer 2012 0.81
71 Rapid curbing of a vancomycin-resistant Enterococcus faecium outbreak in a nephrology department. Clin J Am Soc Nephrol 2009 0.81
72 Treatment of proliferative lupus nephritis--a critical approach. Semin Arthritis Rheum 2006 0.81
73 Treatment of pain in patients with renal insufficiency: the World Health Organization three-step ladder adapted. J Pain 2005 0.81
74 The nephrologist in the HAART era. AIDS 2007 0.81
75 Drug-induced glomerulopathies. Expert Opin Drug Saf 2006 0.81
76 Chronic calcifying pancreatitis and systemic lupus erythematous. Pancreas 2005 0.81
77 Loss of podocyte dysferlin expression is associated with minimal change nephropathy. Am J Kidney Dis 2006 0.81
78 Pharmacokinetics of bevacizumab in haemodialysis. Nephrol Dial Transplant 2006 0.80
79 [Tubular transporters OAT1 and MRP2 and clearance of adefovir]. Nephrol Ther 2005 0.80
80 A case of acute renal failure associated with diffuse infiltrative lymphocytosis syndrome. Nat Clin Pract Nephrol 2008 0.80
81 Topiramate-induced renal tubular acidosis. Am J Med 2004 0.80
82 Why is a shrunken bladder and a nephrotic kidney an expression of the same disease? Nephrol Dial Transplant 2004 0.80
83 [Hemoglobin target in hemodialysis patients]. Nephrol Ther 2006 0.80
84 Lymphopenia in Wegener's granulomatosis. A new clinical activity index? Nephron 2002 0.80
85 Amphotericin B nephrotoxicity. Saudi J Kidney Dis Transpl 2007 0.80
86 [Chemotherapy and renal toxicity]. Bull Cancer 2008 0.79
87 [Incidence and management of anemia in renal transplantation: an observational-French study]. Nephrol Ther 2008 0.79
88 Mortality and cardiovascular morbidity associated with haemoglobin levels: a pooled analysis of randomised controlled trials. Nephron Clin Pract 2014 0.79
89 [Vascular and renal effects of anti-angiogenic therapy]. Nephrol Ther 2008 0.79
90 Using the right MDRD equation. Kidney Int 2004 0.78
91 Antiretroviral drugs and the kidney: further precisions. Kidney Int 2005 0.78
92 The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV. Nephrol Dial Transplant 2004 0.78
93 Hypophosphataemia: an easy strategy for diagnosis and treatment in HIV patients. Antivir Ther 2009 0.78
94 A benefit for renal function after early switch to liposomal amphotericin B from conventional formulation in empirical antifungal treatment. Nephrol Dial Transplant 2007 0.78
95 Acute renal failure in HIV patients. Nephrol Dial Transplant 2007 0.78
96 [Management of targeted therapies in hemodialysis patients]. Bull Cancer 2012 0.78
97 Probenecid-induced membranous nephropathy. Nephrol Dial Transplant 2007 0.78
98 Renal function after aortic stent-grafting including coverage of renal arterial ostia. Am J Kidney Dis 2002 0.77
99 Thalidomide for the nephrologist. Nephrol Dial Transplant 2005 0.77
100 HIV-2 infection and HIV-associated nephropathy. AIDS 2006 0.77
101 Inadequacy of antiretroviral drugs dosage adjustment in HIV patients receiving dialysis. Kidney Int 2003 0.77
102 New therapies for hepatitis C: considerations in patients with renal impairment. Drugs 2014 0.76
103 Nelfinavir and felodipine: a cytochrome P450 3A4-mediated drug interaction. Clin Pharmacol Ther 2004 0.76
104 Endothelin-receptor antagonist/N-acetylcysteine combination in type 1 hepatorenal syndrome. J Hepatol 2009 0.76
105 Detection of vascular access stenosis by measurement of access blood flow from ionic dialysance. Blood Purif 2002 0.76
106 [Management of chemotherapy in hemodialysis patients]. Bull Cancer 2012 0.76
107 [Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant]. Presse Med 2006 0.76
108 Endothelin receptor antagonism-based treatment for scleroderma renal crisis. Am J Kidney Dis 2013 0.76
109 Interstitial nephritis in a patient taking sorafenib. Nephrol Dial Transplant 2007 0.76
110 Renal insufficiency, mortality, and drug management in heart transplant. Results of the CARIN study. Transpl Int 2014 0.76
111 Pharmacokinetics of tramadol in a hemodialysis patient. Nephron 2002 0.76
112 Visipaque (iodixanol) and hexabrix (ioxaglate) in renal insufficiency. J Am Coll Cardiol 2007 0.75
113 Iodixanol and chronic kidney disease. J Invasive Cardiol 2006 0.75
114 Dosing darbepoetin alfa continued. Am J Kidney Dis 2003 0.75
115 Antiretroviral drugs and the kidney: dosage adjustment and renal tolerance. Curr Pharm Des 2004 0.75
116 Hyponatraemic syndrome in a patient with tuberculosis--always the adrenals? Nephrol Dial Transplant 2007 0.75
117 Measuring plasma conductivity to detect sodium load in hemodialysis patients. Clin J Am Soc Nephrol 2008 0.75
118 Reversal of thrombocytopenia in a pregnant woman after changing hemodiafiltration membranes. Am J Kidney Dis 2011 0.75
119 [Letter on the article: "Kidney and HIV infection"]. Presse Med 2012 0.75
120 [Chyluria presenting as milky urine and nephrotic-range proteinuria and milky urine: chyluria or glomerulopathy? Case report and literature review]. Nephrol Ther 2009 0.75
121 [French citizens do not know much about their kidneys... results of a nationwide survey on renal diseases]. Nephrol Ther 2006 0.75
122 Immunosuppressive and calcimimetic drug-drug interactions. Kidney Int 2005 0.75
123 Hyperpnoea and ketonuria in an HIV-infected patient. Nephrol Dial Transplant 2006 0.75
124 Renal consequences of HIV and HIV therapy. Curr Opin HIV AIDS 2007 0.75
125 Oculorenal manifestations in systemic autoimmune diseases. Am J Kidney Dis 2004 0.75
126 Beta-blocker-induced quadriparesis. Ann Intern Med 2004 0.75
127 Doxycycline, gastrointestinal bleeding, and thrombotic microangiopathy. Am J Hematol 2004 0.75
128 Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review. Am J Nephrol 2017 0.75
129 [Peritoneal dialysis as prime treatment for diabetic patient with ESRD]. Nephrol Ther 2006 0.75
130 Atazanavir: a novel inhibitor of HIV-protease in haemodialysis. Nephrol Dial Transplant 2005 0.75
131 [Renal insufficiency and breast cancer]. Bull Cancer 2012 0.75
132 [How to watch over a patient treated with a NSAID in relation to the cardiovascular and renal risk?]. Presse Med 2006 0.75
133 [Drud-induced nephrotoxicity: Bibliography from January 2003 to December 2005]. Nephrol Ther 2006 0.75
134 The Case: An unusual cause of renovascular hypertension. Kidney Int 2009 0.75
135 Epidemiology of microscopic polyarteritis: a 16-year study. Kidney Int 2004 0.75
136 [Is dialysis efficient in the prevention of ionic contrast agent-induced nephropathy?]. Presse Med 2005 0.75
137 [Anticancer drug-induced nephrotoxicity]. Nephrol Ther 2005 0.75
138 [Urinary tract infections during pregnancy]. Rev Prat 2014 0.75
139 [How to watch over a patient treated with a NSAID in relation to the cardiovascular and renal risk?]. Presse Med 2006 0.75
140 FHD: an index to evaluate drug elimination by hemodialysis. Am J Nephrol 2005 0.75
141 Immunoglobulin M 'Flare' after rituximab-associated acute tubular necrosis in Waldenström's macroglobulinemia. Int J Hematol 2009 0.75
142 [Renovascular safety of bevacizumab in breast cancer patients. The prognostic value of hypertension and proteinuria]. Bull Cancer 2015 0.75
143 Lupus nephritis: a review of the current pharmacological treatments. Expert Opin Pharmacother 2004 0.75
144 [Establishing a pilot project for therapeutic education in nephrology]. Rev Infirm 2011 0.75
145 [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?]. Presse Med 2006 0.75
146 [Which information should be given to the patient concerning the cardiovascular and renal risk of the NSAIDs?]. Presse Med 2006 0.75
147 [Which information should be given to the patient concerning the cardiovascular and renal risk of the NSAIDs?]. Presse Med 2006 0.75
148 [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?]. Presse Med 2006 0.75
149 Hepatitis C infection and proteinuria. Kidney Int 2005 0.75
150 Ionic dialysance vs urea clearance in the absence of cardiopulmonary recirculation. Nephrol Dial Transplant 2002 0.75
151 New insight on crescentic glomerulonephritis. Nephrol Dial Transplant 2006 0.75
152 Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study. J Med Virol 2007 0.75
153 [Drug-induced nephrotoxicity: bibliography from January 2003 to December 2004]. Nephrol Ther 2005 0.75
154 Regional citrate anticoagulation during hemodialysis: a simplified procedure using Duocart biofiltration. Blood Purif 2005 0.75
155 Pulmonary hypertension: use of oral drugs in patients with renal insufficiency. Clin Drug Investig 2013 0.75
156 Fanconi and inappropriate secretion of antidiuretic hormone syndromes secondary to venlafaxine therapy. Nephron 2002 0.75
157 Pharmacokinetics and dosage adjustment of rifabutin in a haemodialysis patient. Nephrol Dial Transplant 2002 0.75
158 [What do we know about the cardiovascular toxicity of the NSAIDs?]. Presse Med 2006 0.75
159 Oculo-renal disorders in infectious diseases. Int Ophthalmol 2006 0.75
160 [Kidney diseases in HIV-infected patients]. Nephrol Ther 2009 0.75
161 Prevalence and clinical significance of cryofibrinogenaemia in patients with renal disorders. Nephrol Dial Transplant 2011 0.75
162 Renal disease in cardiovascular disorders: an underrecognized problem. Am J Nephrol 2005 0.75
163 [How to adjust the dose of drugs in chronic kidney disease?]. Rev Prat 2012 0.75
164 Cost of managing anemia in end-stage renal disease: the experience of five French dialysis centers. Eur J Health Econ 2014 0.75
165 Administration of intravenous iron complexes on implantable central venous access port in cancer patients in France: the FERPAC survey. Support Care Cancer 2013 0.75
166 [Renal physiology]. Bull Cancer 2012 0.75
167 Lymphadenopathy and proteinuria. Nephrol Dial Transplant 2004 0.75
168 [What do we know about the cardiovascular toxicity of the NSAIDs?]. Presse Med 2006 0.75
169 [Drugs renal toxicity]. Nephrol Ther 2009 0.75
170 Hemodialysis and ADAMTS-13. Blood Purif 2004 0.75
171 Isonatric dialysis biofeedback in hemodiafiltration with online regeneration of ultrafiltrate (HFR): rationale and study protocol for a randomized controlled study. J Nephrol 2012 0.75